Seroprevalence Study of Hepatitis A, Varicella-Zoster, Cytomegalovirus, Herpes Simplex and Bordetella Pertussis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the seroprevalence of Hepatitis A Virus (HAV), Varicella-Zoster virus (VZV), Cytomegalovirus (CMV), Herpes Simplex (HSV) and Bordetella pertussis (BP)infections in Mexico.

Detailed Description
-----------------
In order to document the epidemiological changes in the sero-prevalence of Hepatitis A, Human simplex virus (1 and 2), Varicella-Zoster virus and Cytomegalovirus infections, we propose to conduct a population based, seroprevalence, cross-sectional study, in Mexico. This will allow the identification of susceptible populations, which in turn, will serve as evidence for the elaboration of recommendations for the prevention of Hepatitis A, Human simplex virus, Varicella-Zoster virus and Cytomegalovirus infection in the region. This study was conducted using data and serum samples from a random sample of subjects that participated in the 2006 National Health and Nutrition Survey.

Official Title
-----------------
Sero-prevalence of Hepatitis A Varicella-Zoster Virus, Cytomegalovirus, Herpes Simplex and Bordetella Pertussis in Mexico

Conditions
-----------------
Viral Hepatitis Vaccines, Hepatitis A, Cytomegalovirus, Varicella-Zoster Virus, Bordetella Pertussis Infection, Herpes Simplex (1 and 2)

Intervention / Treatment
-----------------
* Other: Serum sample


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: • Previously enrolled subjects aged >= 1 to 70 years for National Health and Nutrition Survey 2006 in Mexico, with previously obtained informed consent Exclusion Criteria: Information required for the study is not available or incomplete. Inadequate or insufficient serum sample to detect viral agents required for the study. Serum sample wrongly identified.

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| National Health and Nutrition Survey 2006 (ENSANUT 2006)<br> | Other: Serum sample<br>* Serum samples collected<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Anti-HAV seropositivity status: Subjects with anti-HAV antibody titers >= assay cut-off. |  | 6 to 10 months from study initiation | 
| Anti-Pertussis Toxin seropositivity status for IgG and IgA: Subjects with anti-Pertussis Toxin antibody titers >= assay cut-off for IgG, Subjects with anti-Pertussis Toxin antibody titers >= assay cut-off for IgA |  | 6 to 10 months from study initiation | 
| Anti-VZV seropositivity status: Subjects with anti-VZV antibody titers >= assay cut-off |  | 6 to 10 months from study initiation | 
| Anti-CMV seropositivity status: Subjects with anti-CMV antibody titers >= assay cut-off |  | 6 to 10 months from study initiation | 
| Anti-HSV seropositivity status (defined as the percentage of subjects with anti-HSV 1 and 2 titers >= assay cut-off): Subjects with anti-HSV antibody titers >= assay cut-off |  | 6 to 10 months from study initiation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Difference in HAV, VZV, CMV , HSV and BP seropositivity rates according to socioeconomic status, age group, gender, region, risk group, area and pertussis vaccination status (only for BP analysis) |  | 6 to 10 months from study initiation |